Entera Bio raises $275 million in private placement led by BVF Partners funds

Entera Bio Ltd. entered into a securities purchase agreement on July 26, 2026 with a group of institutional and accredited investors, including funds tied to BVF Partners L.P., for a private placement of ordinary shares and pre-funded warrants. The deal covers an aggregate of 134,803,910 ordinary shares, or pre-funded warrants in lieu of shares, for total proceeds of about $275.0 million, at $2.04 per share.¹ The share price was set at the market under Nasdaq Stock Market rules.¹

The placement closed on July 28, 2026, when Entera issued 122,961,215 ordinary shares and 11,842,695 pre-funded warrants.¹ Each pre-funded warrant carries an exercise price of NIS 0.0000769 per share, is immediately exercisable, and has no expiration date.¹

Entera said it plans to use the net proceeds to support the initiation of its phase 3 registrational study of EB613 in postmenopausal women with osteoporosis, along with general working capital and corporate purposes.¹

Leerink Partners served as lead placement agent, with Evercore ISI, Guggenheim Securities, Cantor Fitzgerald, LifeSci Capital, and Canaccord Genuity acting as co-placement agents.¹

As part of the deal, Entera agreed to grant BVF the right to designate two directors to its board, subject to standard eligibility requirements.¹ That right narrows to one designee if BVF's stake in the securities it acquired falls below 75%, and disappears entirely if it drops below 50% of those securities or below 10% of Entera's total outstanding shares.¹ Separately, directors Haya Taitel and Yonatan Malca each told the board they will resign or not stand for reelection once a corresponding new independent director is appointed.¹ Neither departure stems from any disagreement with the company.¹

Entera also agreed to file a resale registration statement with the SEC within 30 days of closing.¹